Investing.comCodex · 实盘不做把握 2/10
北京时间·🕒 发布 04:20:31时区推断·⟳ 抓取 04:21:42·⚡ 决策 07-29 04:23:25 +1m43s·91.1 天前
Haemonetics任命Martin Madaus进入董事会
本次事件只是董事会成员任命，未披露订单、业绩、监管、资本运作或战略交易等可量化经营增量。
📄 原文Investing.com↗ 原文
Haemonetics elects Martin Madaus to board of directors
Dow, S&P 500 end higher on extended oil slide, solid earnings while Nasdaq falls BOSTON - Haemonetics Corporation (NYSE…
不做 Haemonetics（HAE.US）
常规董事会任命，无明确方向、无可量化短期经营传导，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次事件只是董事会成员任命，未披露订单、业绩、监管、资本运作或战略交易等可量化经营增量。
主要风险
- 董事任命本身通常不构成1-10个交易日内的公司级交易催化。
原文全文
展开原文 · 1,865 字
Dow, S&P 500 end higher on extended oil slide, solid earnings while Nasdaq falls
BOSTON - Haemonetics Corporation (NYSE:HAE) announced today that Martin Madaus has been elected to its board of directors, effective Thursday.
Madaus brings over 30 years of experience in the diagnostics and life sciences tools industries. He currently serves as Senior Operating Executive at The Carlyle Group, a position he has held since 2019, where he advises on healthcare investments and portfolio company performance.
Madaus previously served as Chairman and Chief Executive Officer of Ortho Clinical Diagnostics, Inc., now QuidelOrtho Corporation, where he led the company following its separation from Johnson & Johnson. He also held the position of Chairman, President and Chief Executive Officer of Millipore Corporation, leading the company until its acquisition by Merck KGaA in 2010. Earlier in his career, he served as President and Chief Executive Officer of Roche Diagnostics North America.
Madaus currently serves as Chair of the Board of Repligen Corporation and as a board member of Azenta, Inc. He holds a Doctor of Veterinary Medicine from the University of Munich in Germany and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover in Germany.
"Martin has built and transformed some of the world’s leading healthcare companies and brings deep operational, commercial and strategic leadership experience to our Board," said Ellen Zane, Chair of Haemonetics’ Board of Directors, according to a press release statement.
Haemonetics is a medical technology company with operations in apheresis technologies for plasma and blood collectors, blood management technologies, and interventional technologies including vascular closure systems.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BOSTON - Haemonetics Corporation (NYSE:HAE) announced today that Martin Madaus has been elected to its board of directors, effective Thursday.
Madaus brings over 30 years of experience in the diagnostics and life sciences tools industries. He currently serves as Senior Operating Executive at The Carlyle Group, a position he has held since 2019, where he advises on healthcare investments and portfolio company performance.
Madaus previously served as Chairman and Chief Executive Officer of Ortho Clinical Diagnostics, Inc., now QuidelOrtho Corporation, where he led the company following its separation from Johnson & Johnson. He also held the position of Chairman, President and Chief Executive Officer of Millipore Corporation, leading the company until its acquisition by Merck KGaA in 2010. Earlier in his career, he served as President and Chief Executive Officer of Roche Diagnostics North America.
Madaus currently serves as Chair of the Board of Repligen Corporation and as a board member of Azenta, Inc. He holds a Doctor of Veterinary Medicine from the University of Munich in Germany and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover in Germany.
"Martin has built and transformed some of the world’s leading healthcare companies and brings deep operational, commercial and strategic leadership experience to our Board," said Ellen Zane, Chair of Haemonetics’ Board of Directors, according to a press release statement.
Haemonetics is a medical technology company with operations in apheresis technologies for plasma and blood collectors, blood management technologies, and interventional technologies including vascular closure systems.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。